H.C. Wainwright raised the firm’s price target on AxoGen (AXGN) to $39 from $26 and keeps a Buy rating on the shares after the company announced that the FDA had approved the Biologics License Application for its Avance acellular nerve scaffold. The approval further strengthens Avance’s market positioning and should facilitate further market penetration of Avance in the coming years, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN:
- AxoGen price target raised to $37 from $27 at Canaccord
- Midday Fly By: Meta to slash metaverse spending, Salesforce posts Q3 beat
- AxoGen price target raised to $40 from $30 at Lake Street
- AxoGen price target raised to $36 from $29 at Jefferies
- AxoGen announces FDA approval of Avance biologics license application